ClinicalTrials.gg
RecruitingNCT06512662PAKO-HDJUpdated Apr 6, 2026

Support Pathway for ENT Cancer Patients in a Support Care Day Hospital

An interventional study of Consultations with paramedics in Otorhinolaryngologic Neoplasms, sponsored by Clinique Pasteur Lanroze. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-06.

Primary conditionAnxiety Disorders(the registry's first term)UnverifiedIs this wrong?The registry often attaches Anxiety Disorders to studies about something else, and this study's title and listed conditions do not name it. No better condition is named, so the registry's term is kept.

Sponsored by Clinique Pasteur Lanroze · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Cancers of the upper respiratory / digestive tract are a major public health problem, ranking 5th among the most common cancers. Surgery plays a central role in the recommended treatments for this type of pathology. The surgical procedure and its after-effects can be anxiety-provoking and have a major psychological, physical and social impact on patients over the long term.

Our institution's standard protocol is based on a pre-operative supportive care day hospital. The aim of this study is to compare our current care pathway with a more extensive interdisciplinary care pathway focused on patients' needs, in order to reduce anxiety and improve the quality of life of patients undergoing surgery for cancers of the upper respiratory / digestive tract.

Our aim is to use a prospective single-centre interventional study to assess the impact of adding three post-operative day hospitals to the existing care pathway in terms of reducing anxiety and improving the quality of life of patients undergoing surgery.

02

Conditions studied

  • Otorhinolaryngologic Neoplasms

Browse trials for

Keywords

  • surgery
  • quality of life
  • anxiety
  • supportive care
03

In context

Anxiety Disorders Unverified

7,249 studies on the registry are indexed under Anxiety Disorders; 1,691 are open to participants now.

This study's planned enrollment of 60 is below the median of 80 across 6,103 interventional studies indexed under Anxiety Disorders.

Browse Anxiety Disorders studies →

Lead sponsor

Clinique Pasteur Lanroze is the lead sponsor of 3 studies on the registry; 3 are open to participants now.

Compared within Anxiety Disorders, the registry's first condition term, which may not be this study's main condition. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patient undergoing surgery for VADS cancer requiring at least one night's post-operative hospitalisation
  • Understanding of spoken and written French
  • Patient covered by a social security scheme

Exclusion criteria

Exclusion Criteria:

  • Protected patient under a protective measure or legal safeguard
  • Pregnant or breast-feeding patients
  • Patients suffering from major cognitive disorders
  • Patients with major anxiety disorders prior to the onset of cancer
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • No intervention
    Control
  • Experimental
    Supportive care

    Procedure: Consultations with paramedics

Interventions

  • ProcedureConsultations with paramedics

    Patients of experimental arm will beneficiate of supplemental consultations with paramedics intervenants at 1 month, 3 months and 6 months after surgery : * dietetician * speech therapist * psychologist * advanced practice nurse During these consultations, several scales will be performed to assess the patient's condition (anxiety, nutritional status, psychological condition, speech therapy status).

06

What researchers measure

Primary outcomes

  1. Anxiety

    Anxiety evaluation by State Trait Anxiety Inventory (STAI) scale. It is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.

    Time frame: 1 month ; 3 months ; 6 months

Secondary outcomes

  1. Quality of life evaluation

    Quality of life will be evaluated by EORTC C30. The EORTC quality of life questionnaire (QLQ) is an integrated system for assessing the health-related quality of life (QoL) of cancer patients participating in international clinical trials.

    Time frame: 1 month ; 3 months ; 6 months

  2. pain evaluation

    Pain will be assessed using a visual analogue scale from 0 (no pain) to 10 (worst pain imaginable).

    Time frame: 1 month ; 3 months ; 6 months

  3. Toxic behaviour (tobacco and alcohol) evaluation

    Tobacco (number of cigarettes per day) and alcohol (number of units per day) consumption will be evaluated by questioning the patient.

    Time frame: 1 month ; 3 months ; 6 months

  4. Weight status evaluation

    Weight statut will be determined by calculating the body mass index (BMI) and the percentage of loss weight.

    Time frame: 1 month ; 3 months ; 6 months

  5. nutritional status evaluation

    Nutritional status will be evaluated using SEFI (simple evaluation of food intake) scale. This scale is a Likert scale to assess the portion eaten at mealtimes, from 0 ("I haven't eaten anything") to 10 ('I have eaten everything").

    Time frame: 1 month ; 3 months ; 6 months

  6. swallowing assessment

    Swallowing is measured by Deglutition Handicap Index (DHI). It is a questionnaire with 30 questions (10 physical, 10 functional, 10 emotional) with a Likert scale from "never" to "always".

    Time frame: 1 month ; 3 months ; 6 months

  7. vocal status assessment

    Vocal status is measured by Vocal Handicap Index (VHI). It is a questionnaire with 30 questions with a Likert scale from "never" to "always".

    Time frame: 1 month ; 3 months ; 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Dec 2026, 26 months after the start.

Of 3,871 non-industry interventional studies with no phase under Anxiety Disorders, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 28. This study's planned 26 months is above that.

Counting every sponsor, half of 3,976 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 16, 2024
First posted
Jul 22, 2024
StartActual
Oct 8, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Apr 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06512662
Lead sponsor
Clinique Pasteur Lanroze
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Oct 8, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Apr 6, 2026

Study contacts

Camille Vuarin, APN
Contact
cvuarin@chp-brest.bzh
+33 2 98 34 20 31 ext. 552031

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion